These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology. Stoyas CA; La Spada AR Handb Clin Neurol; 2018; 147():143-170. PubMed ID: 29325609 [TBL] [Abstract][Full Text] [Related]
6. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Ghosh S; Feany MB Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017 [TBL] [Abstract][Full Text] [Related]
7. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Yue S; Serra HG; Zoghbi HY; Orr HT Hum Mol Genet; 2001 Jan; 10(1):25-30. PubMed ID: 11136710 [TBL] [Abstract][Full Text] [Related]
8. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Trottier Y; Lutz Y; Stevanin G; Imbert G; Devys D; Cancel G; Saudou F; Weber C; David G; Tora L Nature; 1995 Nov; 378(6555):403-6. PubMed ID: 7477379 [TBL] [Abstract][Full Text] [Related]
9. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease. Truant R; Atwal RS; Burtnik A Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517 [TBL] [Abstract][Full Text] [Related]
10. Peptide models for inherited neurodegenerative disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions. Sharma D; Sharma S; Pasha S; Brahmachari SK FEBS Lett; 1999 Jul; 456(1):181-5. PubMed ID: 10452554 [TBL] [Abstract][Full Text] [Related]
11. Spinocerebellar ataxia type 1--modeling the pathogenesis of a polyglutamine neurodegenerative disorder in transgenic mice. Clark HB; Orr HT J Neuropathol Exp Neurol; 2000 Apr; 59(4):265-70. PubMed ID: 10759181 [TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Branco J; Al-Ramahi I; Ukani L; Pérez AM; Fernandez-Funez P; Rincón-Limas D; Botas J Hum Mol Genet; 2008 Feb; 17(3):376-90. PubMed ID: 17984172 [TBL] [Abstract][Full Text] [Related]
13. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897 [TBL] [Abstract][Full Text] [Related]
17. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. Bonini NM; Gitler AD J Mol Neurosci; 2011 Nov; 45(3):676-83. PubMed ID: 21660502 [TBL] [Abstract][Full Text] [Related]
18. Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Lunkes A; Trottier Y; Fagart J; Schultz P; Zeder-Lutz G; Moras D; Mandel JL Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1013-9. PubMed ID: 10434300 [TBL] [Abstract][Full Text] [Related]